CovidChloroV1, Main, Exploration, bibRecord, 000089

The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.

Identifieur interne : 000089 ( Main/Exploration ); précédent : 000088; suivant : 000090

The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.

Auteurs : Kimberley Lewis [Canada] ; Dipayan Chaudhuri [Canada] ; Fayez Alshamsi [Émirats arabes unis] ; Laiya Carayannopoulos [Canada] ; Karin Dearness [Canada] ; Zain Chagla [Canada] ; Waleed Alhazzani [Canada]

Source :

PloS one [ 1932-6203 ] ; 2021.

RBID : pubmed:33406138

Descripteurs français

KwdFr :
- Antibioprophylaxie (méthodes), Antiviraux (usage thérapeutique), Essais contrôlés randomisés comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (métabolisme), Hydroxychloroquine (usage thérapeutique), Prophylaxie pré-exposition (méthodes).
MESH :
- effets indésirables : Hydroxychloroquine.
- métabolisme : Hydroxychloroquine.
- méthodes : Antibioprophylaxie, Prophylaxie pré-exposition.
- usage thérapeutique : Antiviraux, Hydroxychloroquine.
- Essais contrôlés randomisés comme sujet, Humains.

English descriptors

KwdEn :
- Antibiotic Prophylaxis (methods), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (metabolism), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (metabolism), Hydroxychloroquine (therapeutic use), Pre-Exposure Prophylaxis (methods), Randomized Controlled Trials as Topic (MeSH), SARS-CoV-2 (pathogenicity).
MESH :
- chemical , adverse effects : Hydroxychloroquine.
- chemical , metabolism : Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine.
- drug therapy : COVID-19.
- metabolism : COVID-19.
- methods : Antibiotic Prophylaxis, Pre-Exposure Prophylaxis.
- pathogenicity : SARS-CoV-2.
- Humans, Randomized Controlled Trials as Topic.

Abstract

BACKGROUND

Populations such as healthcare workers (HCW) that are unable to practice physical distancing are at high risk of acquiring Coronavirus disease-2019 (COVID-19). In these cases pharmacological prophylaxis would be a solution to reduce severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) transmission. Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2. We therefore sought to determine the efficacy and safety of hydroxychloroquine as prophylaxis for COVID-19.

METHODS AND FINDINGS

We electronically searched EMBASE, MEDLINE, the Cochrane COVID-19 Register of Controlled Trials, Epistemonikos COVID-19, clinicaltrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to September 28th, 2020 for randomized controlled trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes with the corresponding 95% confidence intervals (CIs) using a random-effect model. We identified four RCTs (n = 4921) that met our eligibility criteria. The use of hydroxychloroquine, compared to placebo, did not reduce the risks of developing COVID-19 (RR 0.82, 95% CI 0.65 to 1.04, moderate certainty), hospitalization (RR 0.72, 95% CI 0.34 to 1.50, moderate certainty), or mortality (RR 3.26, 95% CI 0.13 to 79.74, low certainty), however, hydroxychloroquine use increased the risk of adverse events (RR 2.76, 95% CI 1.38 to 5.55, moderate certainty).

CONCLUSION

Although pharmacologic prophylaxis is an attractive preventive strategy against COVID-19, the current body of evidence failed to show clinical benefit for prophylactic hydroxychloroquine and showed a higher risk of adverse events when compared to placebo or no prophylaxis.

DOI: 10.1371/journal.pone.0244778
PubMed: 33406138
PubMed Central: PMC7787432

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000547
to stream Main, to step Curation: 000547

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.</title>
<author><name sortKey="Lewis, Kimberley" sort="Lewis, Kimberley" uniqKey="Lewis K" first="Kimberley" last="Lewis">Kimberley Lewis</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chaudhuri, Dipayan" sort="Chaudhuri, Dipayan" uniqKey="Chaudhuri D" first="Dipayan" last="Chaudhuri">Dipayan Chaudhuri</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alshamsi, Fayez" sort="Alshamsi, Fayez" uniqKey="Alshamsi F" first="Fayez" last="Alshamsi">Fayez Alshamsi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.</nlm:affiliation>
<country xml:lang="fr">Émirats arabes unis</country>
<wicri:regionArea>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain</wicri:regionArea>
<wicri:noRegion>Al Ain</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carayannopoulos, Laiya" sort="Carayannopoulos, Laiya" uniqKey="Carayannopoulos L" first="Laiya" last="Carayannopoulos">Laiya Carayannopoulos</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dearness, Karin" sort="Dearness, Karin" uniqKey="Dearness K" first="Karin" last="Dearness">Karin Dearness</name>
<affiliation wicri:level="1"><nlm:affiliation>St. Joseph's Healthcare Hamilton, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>St. Joseph's Healthcare Hamilton, Hamilton</wicri:regionArea>
<wicri:noRegion>Hamilton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chagla, Zain" sort="Chagla, Zain" uniqKey="Chagla Z" first="Zain" last="Chagla">Zain Chagla</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alhazzani, Waleed" sort="Alhazzani, Waleed" uniqKey="Alhazzani W" first="Waleed" last="Alhazzani">Waleed Alhazzani</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33406138</idno>
<idno type="pmid">33406138</idno>
<idno type="doi">10.1371/journal.pone.0244778</idno>
<idno type="pmc">PMC7787432</idno>
<idno type="wicri:Area/Main/Corpus">000547</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000547</idno>
<idno type="wicri:Area/Main/Curation">000547</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000547</idno>
<idno type="wicri:Area/Main/Exploration">000547</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.</title>
<author><name sortKey="Lewis, Kimberley" sort="Lewis, Kimberley" uniqKey="Lewis K" first="Kimberley" last="Lewis">Kimberley Lewis</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chaudhuri, Dipayan" sort="Chaudhuri, Dipayan" uniqKey="Chaudhuri D" first="Dipayan" last="Chaudhuri">Dipayan Chaudhuri</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alshamsi, Fayez" sort="Alshamsi, Fayez" uniqKey="Alshamsi F" first="Fayez" last="Alshamsi">Fayez Alshamsi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.</nlm:affiliation>
<country xml:lang="fr">Émirats arabes unis</country>
<wicri:regionArea>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain</wicri:regionArea>
<wicri:noRegion>Al Ain</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carayannopoulos, Laiya" sort="Carayannopoulos, Laiya" uniqKey="Carayannopoulos L" first="Laiya" last="Carayannopoulos">Laiya Carayannopoulos</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dearness, Karin" sort="Dearness, Karin" uniqKey="Dearness K" first="Karin" last="Dearness">Karin Dearness</name>
<affiliation wicri:level="1"><nlm:affiliation>St. Joseph's Healthcare Hamilton, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>St. Joseph's Healthcare Hamilton, Hamilton</wicri:regionArea>
<wicri:noRegion>Hamilton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chagla, Zain" sort="Chagla, Zain" uniqKey="Chagla Z" first="Zain" last="Chagla">Zain Chagla</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alhazzani, Waleed" sort="Alhazzani, Waleed" uniqKey="Alhazzani W" first="Waleed" last="Alhazzani">Waleed Alhazzani</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibiotic Prophylaxis (methods)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (metabolism)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pre-Exposure Prophylaxis (methods)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antibioprophylaxie (méthodes)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (métabolisme)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Prophylaxie pré-exposition (méthodes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Antibiotic Prophylaxis</term>
<term>Pre-Exposure Prophylaxis</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Antibioprophylaxie</term>
<term>Prophylaxie pré-exposition</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Populations such as healthcare workers (HCW) that are unable to practice physical distancing are at high risk of acquiring Coronavirus disease-2019 (COVID-19). In these cases pharmacological prophylaxis would be a solution to reduce severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) transmission. Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2. We therefore sought to determine the efficacy and safety of hydroxychloroquine as prophylaxis for COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS AND FINDINGS</b>
</p>
<p>We electronically searched EMBASE, MEDLINE, the Cochrane COVID-19 Register of Controlled Trials, Epistemonikos COVID-19, clinicaltrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to September 28th, 2020 for randomized controlled trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes with the corresponding 95% confidence intervals (CIs) using a random-effect model. We identified four RCTs (n = 4921) that met our eligibility criteria. The use of hydroxychloroquine, compared to placebo, did not reduce the risks of developing COVID-19 (RR 0.82, 95% CI 0.65 to 1.04, moderate certainty), hospitalization (RR 0.72, 95% CI 0.34 to 1.50, moderate certainty), or mortality (RR 3.26, 95% CI 0.13 to 79.74, low certainty), however, hydroxychloroquine use increased the risk of adverse events (RR 2.76, 95% CI 1.38 to 5.55, moderate certainty).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Although pharmacologic prophylaxis is an attractive preventive strategy against COVID-19, the current body of evidence failed to show clinical benefit for prophylactic hydroxychloroquine and showed a higher risk of adverse events when compared to placebo or no prophylaxis.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33406138</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>16</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS One</ISOAbbreviation>
</Journal>
<ArticleTitle>The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.</ArticleTitle>
<Pagination><MedlinePgn>e0244778</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0244778</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Populations such as healthcare workers (HCW) that are unable to practice physical distancing are at high risk of acquiring Coronavirus disease-2019 (COVID-19). In these cases pharmacological prophylaxis would be a solution to reduce severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) transmission. Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2. We therefore sought to determine the efficacy and safety of hydroxychloroquine as prophylaxis for COVID-19.</AbstractText>
<AbstractText Label="METHODS AND FINDINGS">We electronically searched EMBASE, MEDLINE, the Cochrane COVID-19 Register of Controlled Trials, Epistemonikos COVID-19, clinicaltrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to September 28th, 2020 for randomized controlled trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes with the corresponding 95% confidence intervals (CIs) using a random-effect model. We identified four RCTs (n = 4921) that met our eligibility criteria. The use of hydroxychloroquine, compared to placebo, did not reduce the risks of developing COVID-19 (RR 0.82, 95% CI 0.65 to 1.04, moderate certainty), hospitalization (RR 0.72, 95% CI 0.34 to 1.50, moderate certainty), or mortality (RR 3.26, 95% CI 0.13 to 79.74, low certainty), however, hydroxychloroquine use increased the risk of adverse events (RR 2.76, 95% CI 1.38 to 5.55, moderate certainty).</AbstractText>
<AbstractText Label="CONCLUSION">Although pharmacologic prophylaxis is an attractive preventive strategy against COVID-19, the current body of evidence failed to show clinical benefit for prophylactic hydroxychloroquine and showed a higher risk of adverse events when compared to placebo or no prophylaxis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName>
<ForeName>Kimberley</ForeName>
<Initials>K</Initials>
<Identifier Source="ORCID">0000-0001-6610-3369</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chaudhuri</LastName>
<ForeName>Dipayan</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Alshamsi</LastName>
<ForeName>Fayez</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">0000-0002-9121-4279</Identifier>
<AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Carayannopoulos</LastName>
<ForeName>Laiya</ForeName>
<Initials>L</Initials>
<Identifier Source="ORCID">0000-0001-9041-9216</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dearness</LastName>
<ForeName>Karin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>St. Joseph's Healthcare Hamilton, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chagla</LastName>
<ForeName>Zain</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Alhazzani</LastName>
<ForeName>Waleed</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>GUIDE Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>01</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065129" MajorTopicYN="N">Pre-Exposure Prophylaxis</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>10</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>12</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>6</Day>
<Hour>17</Hour>
<Minute>13</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33406138</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0244778</ArticleId>
<ArticleId IdType="pii">PONE-D-20-31832</ArticleId>
<ArticleId IdType="pmc">PMC7787432</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Contemp Clin Trials. 2015 Nov;45(Pt A):139-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26343745</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Nov 5;71(8):1943-1946</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32301964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23917901</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2018 Dec;14(12):693-703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30401979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9310563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 24;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33289973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertens Res. 2020 Jul;43(7):648-654</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32341442</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Sep 30;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33001138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2020 Aug;26(8):979-987</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32470568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2008 Apr 26;336(7650):924-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18436948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 2018 Apr;27(5):847-852</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28862574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 14;323(14):1335</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32181795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Res Methodol. 2020 Jan 16;20(1):10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31948397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 19;383(21):2041-2052</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32706953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jun;55(6):105988</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Oct 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33068425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Oct;63(10):1515-1521</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32418114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
<li>Émirats arabes unis</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Hamilton (Ontario)</li>
</settlement>
<orgName><li>Université McMaster</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Lewis, Kimberley" sort="Lewis, Kimberley" uniqKey="Lewis K" first="Kimberley" last="Lewis">Kimberley Lewis</name>
</region>
<name sortKey="Alhazzani, Waleed" sort="Alhazzani, Waleed" uniqKey="Alhazzani W" first="Waleed" last="Alhazzani">Waleed Alhazzani</name>
<name sortKey="Alhazzani, Waleed" sort="Alhazzani, Waleed" uniqKey="Alhazzani W" first="Waleed" last="Alhazzani">Waleed Alhazzani</name>
<name sortKey="Carayannopoulos, Laiya" sort="Carayannopoulos, Laiya" uniqKey="Carayannopoulos L" first="Laiya" last="Carayannopoulos">Laiya Carayannopoulos</name>
<name sortKey="Chagla, Zain" sort="Chagla, Zain" uniqKey="Chagla Z" first="Zain" last="Chagla">Zain Chagla</name>
<name sortKey="Chaudhuri, Dipayan" sort="Chaudhuri, Dipayan" uniqKey="Chaudhuri D" first="Dipayan" last="Chaudhuri">Dipayan Chaudhuri</name>
<name sortKey="Chaudhuri, Dipayan" sort="Chaudhuri, Dipayan" uniqKey="Chaudhuri D" first="Dipayan" last="Chaudhuri">Dipayan Chaudhuri</name>
<name sortKey="Dearness, Karin" sort="Dearness, Karin" uniqKey="Dearness K" first="Karin" last="Dearness">Karin Dearness</name>
<name sortKey="Lewis, Kimberley" sort="Lewis, Kimberley" uniqKey="Lewis K" first="Kimberley" last="Lewis">Kimberley Lewis</name>
</country>
<country name="Émirats arabes unis"><noRegion><name sortKey="Alshamsi, Fayez" sort="Alshamsi, Fayez" uniqKey="Alshamsi F" first="Fayez" last="Alshamsi">Fayez Alshamsi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000089 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000089 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33406138
   |texte=   The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33406138" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.

The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki